Regenerative Medicine / Advanced Wound Care / Biotech Medical Devices
Strategic Profile
The company's product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. CMS shifted reimbursement to support high-quality, evidence-backed PMA products while reducing payment for non-PMA products, which is favorable to Organogenesis' portfolio. The company initiated a rolling BLA submission for ReNu late last year and expects to complete it in the first half of 2026, describing it as a potential transformational opportunity if approved by the FDA for knee osteoarthritis pain.
Cyborg Score Rationale
Strong Q4 2025 results with record revenue and substantial YoY growth demonstrate operational strength. However, the company expects full-year 2026 total net revenue to decline 25% to 38% year-over-year due to clinician confusion from CMS policy changes, creating significant near-term headwinds despite long-term strategic positioning.
Top Insights
Record Q4 2025 revenue of $225.1M, up 78% YoY, with advanced wound care sales up 83%, demonstrating strong market demand pre-disruption
CMS December 30 comments on discarded products created material disruption impacting utilization of PMA-approved products in early 2026
Company has strong balance sheet with $94.3M in cash, no debt, and a $75M revolver, plus investments in new Smithfield, RI manufacturing/R&D center
Rolling BLA for ReNu (for knee osteoarthritis) expected to complete in H1 2026, described as transformational opportunity
Named Competitors
Skin Substitutes and Wound Care Products — Traditional wound care and surgical matrix competitors
Bioengineered Tissue Solutions — Regenerative medicine and tissue allografts
Advanced Wound Care — Negative pressure therapy and wound management